ALPN News and Press, Alpine Immune Sciences Inc. From 09/05/23

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company will present new preclinical data from a study of povetacicept in a murine experimental au...

2023-08-31 10:00:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the successful initiation of the second IgA nephropathy (IgAN) dose cohort in RUBY-3, a phase 1b/2a study i...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of M. Christina Yi to Chief Technology Officer effective August 21, 2023. Ms. Yi has ...

2023-08-16 17:08:22 ET Summary Alpine Immune Sciences reported better-than-expected Q2 2023 results, with a loss per share of $0.27 and revenues of $8.6 million. The company's trials for ALPN-303 and ALPN-101 are progressing smoothly, with RUBY-3 preliminary data to be presented i...

Shares of Alpine Immune Sciences, Inc. (NASDAQ: ALPN) traded at a new 52-week high today and are currently trading at $14.05. So far today, approximately 45,824 shares have been exchanged, as compared to an average 30-day volume of 264.76k shares. Alpine Immune Sciences, Inc., a clinical-stag...

--The Company will present preliminary data from RUBY-3 glomerulonephritis clinical study at the American Society of Nephrology Meeting in November 2023-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative tre...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers, at ...

2023-05-11 17:24:26 ET Alpine Immune Sciences press release ( NASDAQ: ALPN ): Q1 GAAP EPS of -$0.28 beats by $0.09 . Revenue of $9.4M (-31.0% Y/Y) beats by $2.52M . As of March 31, 2023, Alpine’s cash and investments totaled $248.3 million, which the C...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2023. “So far this year, we have ac...